Skip to main content

Table 1 Demographic and clinico-pathological characteristics of endometrial cancer subjects from institutional and national endometrial cancer database

From: Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma

  Institutional database National database
LVSI absent (N = 227) LVSI present (N = 48) Total (N = 275) p value LVSI absent (N = 24,035)
n (%)
LVSI present (N = 3766)
n (%)
Total (N = 27,801)
n (%)
p value
Age mean (SD) (n = 275) 63.2 (10.5) 64.8 (9.8) 63.5 (10.3) 0.3 61.6 (10.5) 64.1 (9.8) 61.9 (10.4) < 0.001
Race (n = 274)     0.3     0.35
 White 179 (79.2%) 32 (66.7%) 211 (77.0%)   21,201 (88.2) 3336 (88.5) 24,537 (88.3)  
 African American 38 (16.8%) 10 (20.8%) 48 (17.5%)   1551 (6.4) 228 (6.1) 1779 (6.4)  
 Asian 2 (0.9%) 1 (2.1%) 3 (1.1%)   534 (2.2) 102 (2.7) 636 (2.3)  
 Native American, Alaskan Native 1 (0.4%) 1 (2.1%) 2 (0.7%)   
 Native Hawaiian, Pacific Islander 1 (0.4%) 1 (2.1%) 2 (0.7%)   
 Other 3 (1.4%) 1 (2.1%) 4 (1.5%)   496 (2.1) 71 (1.9) 567 (2.0)  
 Unknown 2 (0.9%) 2 (4.1%) 4 (1.5%)   253 (1.1) 29 (0.8) 282 (1.0)  
Stage (n = 269)     0.047     < 0.001
 Ia 84 (38.0%) 11 (22.9%) 95 (35.3%)   18,713 (77.9) 1651(43.8) 20,364 (73.2)  
 Ib 137 (62.0%) 37 (77.1%) 174 (64.7%)   5322 (22.1) 2115 (56.2) 7437 (26.8)  
Grade (n = 275)     < 0.001*     < 0.001*
 1 120 (52.9%) 8 (16.7%) 128 (46.5%)   10,832 (45.1) 873 (23.1) 11,705 (42.1)  
 2 77 (33.9%) 22 (45.8%) 99 (36.0%)   7165 (29.8) 1282 (34.2) 8447 (30.4)  
 3 30 (13.2%) 18 (37.5%) 48 (17.5%)   2552 (10.6) 1070 (28.5) 3622 (13.1)  
 Unknown   3486 (14.5) 541 (14.2) 4027 (14.4)  
Depth of invasion (n = 275)     < 0.001     
 Inner 1/3 146 (64.3%) 16 (33.3%) 162 (58.9%)   
 Middle 1/3 59 (26.0%) 17 (35.4%) 76 (27.6%)   
 Outer 1/3 22 (9.7%) 15 (31.3%) 37 (13.5%)   
High-intermediate risk (n = 275)     < 0.001     < 0.001
 No 178 (78.4%) 9 (18.7%) 187 (68%)   12,631 (52.8) 657 (17.5) 13,288 (48.0)  
 Yes 49 (21.6%) 39 (81.3%) 88 (32%)   11,404 (47.2) 3109 (82.5) 14,513 (52.0)  
Adjuvant therapy (n = 63)     0.15**     < 0.001**
 External beam radiation therapy 2 (0.9%) 8 (16.7%) 10 (3.6%)   394 (1.6) 349 (9.4) 743 (2.7)  
 Vaginal brachytherapy 16 (7.1%) 14 (29.2%) 30 (10.9%)   3788 (15.7) 1520 (40.3) 5308 (19.0)  
 Hormonal 8 (3.9%) 5 (14.7%) 13 (5.4%)   115 (0.5) 16 (0.4) 131 (0.5)  
 Chemotherapy 3 (1.5%) 6 (17.1%) 9 (3.8%)   915 (3.8) 520 (13.8) 1435 (5.2)  
 Other 1 (0.4%) 0 (0%) 1 (0.4%)   1 (0.004) 2 (0.1) 3 (0.01)  
 No additional treatment   18,822 (78.4) 1359 (36.0) 20,181 (72.6)  
  1. Proportions are compared using a chi-square test, and age is compared using an independent t test
  2. SD standard deviation
  3. *For comparing grades 1 and 2 to 3
  4. **Excludes other categories due to small sample size in this group